Visual function and visual quality in diabetic macular edema treated by Conbercept / 国际眼科杂志(Guoji Yanke Zazhi)
International Eye Science
;
(12): 127-129, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-906747
ABSTRACT
@#AIM:
To evaluate the visual function and visual quality of patients with diabetic macular edema treated with conbercept injection.<p>METHODS:
The average change of contrast sensitivity(CS), best corrected visual acuity(BCVA), central retinal thickness(CRT)and NEIVFQ-25 score were observed for 3mo after intravitreal injection of conbercept in 43 eyes of 38 patients with diabetic macular edema.<p>RESULTS:
The mean CS increased from(1.060±0.14)units to(1.47±0.31)units at 12wk after intravitreal injection of conbercept(<i>P</i><0.05). The average LogMAR BCVA decreased significantly from 0.535±3.32 to 0.333±0.11 at 12wk(<i>P</i><0.05), and the average CRT decreased significantly from 369.45±36.42μm to 226.53±39.48μm at 12wk(<i>P</i><0.05). There is not a correlation between the changes in CRT and BCVA and the improvement of CS. The NEIVFQ-25 score improved in 30 cases(79%)from baseline to 12wk. 6 cases(16%)had no change in the NEIVFQ-25 score, and 2 cases(5%)declined in the NEIVFQ-25 score.<p>CONCLUSION:
The treatment of conbercept injection for diabetic retinal macular edema can significantly improve the visual function and the quality of life.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
International Eye Science
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS